- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- dasatinib, Rituximab, fludarabine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoarthritis
- Interventions
- Adalimumab
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Fibrodysplasia Ossificans Progressiva (FOP)
- Interventions
- Anti-IL1 Therapy
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Years to 30 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Systemic Sclerosis
- Interventions
- Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine
- Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
- Interventions
- Bevacizumab, Dasatinib, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- Anne Noonan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
- Interventions
- Daptomycin, Vancomycin
- Drug
- Lead sponsor
- Mountain Home Research & Education Corporation
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Johnson City, Tennessee • Mountain Home, Tennessee
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Drug
- Lead sponsor
- Nexstar Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Los Angeles, California • Palm Springs, California + 9 more
- Conditions
- Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
- Interventions
- MEDI3617, Bevacizumab, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo
- Biological · Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab, Paclitaxel, Trastuzumab emtansine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 62 more
- Conditions
- Ependymoma, Anaplastic Ependymoma
- Interventions
- Carboplatin, Bevacizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
- Interventions
- SBP-101, nab-paclitaxel, Gemcitabine Injection
- Drug
- Lead sponsor
- Panbela Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- La Jolla, California • Gainesville, Florida • Rochester, New York
- Conditions
- Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
- Interventions
- BOTOX-A, Saline injection
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- Taxotere, Cytoxan, Herceptin
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 62 more
- Conditions
- Immune System Diseases
- Interventions
- Food proteins, Omalizumab
- Dietary Supplement · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Renal Cell Carcinoma
- Interventions
- Entinostat, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Roberto Pili
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Indianapolis, Indiana
- Conditions
- Inherited Metabolic Storage Diseases
- Interventions
- CAMPATH-1H, Anti-CD45, FK506, Fludarabine
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Ustekinumab, Placebo
- Drug · Other
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild
- Interventions
- Darbepoetin Alfa, Normal Saline
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 1 Hour to 24 Hours
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Prematurity
- Interventions
- Amino acids
- Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- Up to 18 Hours
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- GU Research Network, LLC
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska